Pasithea Therapeutics Corp. (KTTA) stock
KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.51+0.08 (+17.64%)
Close on Nov 18, 2026Market cap $17.07MP/E –Yield –
Pasithea Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Pasithea Therapeutics's price to sales ratio was 18.7× on Apr 28, 2023.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 18.7× | – |
See a number that looks wrong?